News and Announcements
Mustang Resources on Target for Ruby Inventory as another Deposit is Discovered
- Published June 28, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Mustang Resources (ASX: MUS) is pleased to announce that its ruby inventory has grown to 120,397 cts , placing the company comfortably on schedule to meet its target of 200,000cts in time for its first closed bid tender in October this year.
KEY TAKEAWAYS:
- Mustang firmly on track for first sale of 200,000cts in October with inventory already hitting 120,000cts
- Rapid inventory growth due in part to success of upgraded processing plant at Montepuez ruby project
- Initial bulk sample confirms significant new ruby discovery on recently acquired licence
- Shallow secondary deposit, with initial bulk sample of 5,692 m3 delivering 4,445 cts of gem quality rubies
- Consistent recovery of stones classed in the special/premium category
- Extensive secondary ruby mineralisation proven over 2,200m strike (open ended)
Mustang Managing Director Christiaan Jordaan said the Company’s strategy to generate substantial cashflow from Montepuez was well on track.
“The successful commissioning of our upgraded plant and the growth in our ruby inventory should ensure we achieve a 200,000-carat inventory before October,” Mr Jordaan said.
“This will underpin our first closed bid tender and enable Mustang to demonstrate the cashflow potential of Montepuez.
“Work is now underway to select a safe-house facility and tender location. These sites are expected to be finalised within two months.”
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
